Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biosimilar Rituximab (RTXM83) vs Reference Rituximab in DLBCL
NCT02268045Phase 3Completed
- Sponsor
- mAbxience
- Start
- May 2013
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by mAbxience. Started May 2013; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02268045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268045.